A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology<br />How to maximize medical techn...
Background<br /><ul><li>B.Sc.	Honors Life Science</li></ul>			McMaster University, Canada<br /><ul><li>Ph.D.	Medical Bioph...
Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
Area of Business/Research Focus
Rapid Innovation / Adoption
Surgeon Involvement During Product Development
The Benefits of Early Involvement</li></li></ul><li>Who is C.R. Bard, Inc. ?<br /><ul><li>C.R. Bard, Inc. was founded in 1...
A publicly traded company – BCR
Market Cap: $9.3B, Annual Revenue of $2.8B
11,700 employees worldwide
Headquartered in Murray Hill, NJ
5 divisions - RI, Massachusetts, Georgia, Utah, Arizona
Vascular, Urology, Oncology, Surgical Specialties
Global presence </li></ul>	Europe, Japan, Canada, Australia, Latin America, Asia, China<br />
Davol, Inc. History<br />Joseph Davol<br />Charles Davol<br />
Davol, Inc. History<br />1874: Davol Rubber Company founded to produce 	rubber medical and surgical supplies such as hot 	...
C.R. Bard, Inc. (Davol) Today<br />Worldwide Leader in a $600M Hernia Repair Market<br /><ul><li>Provide innovative soluti...
Broadest/deepest product line in the industry
Portfolio of patented, proprietary products
Highly trained, professional sales team - surgeon consultants
Innovative Marketing Programs
Surgeon training
 Patient education and awareness</li></li></ul><li>Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
Area of Business/Research Focus
Rapid Innovation / Adoption
Surgeon InvolvementDuring Product Development
The Benefits of Early Involvement</li></li></ul><li>Soft Tissue Reconstruction – Hernia Repair<br />
Soft Tissue Reconstruction – Hernia Repair<br />
Soft Tissue Reconstruction – Breast Reconstruction<br />
Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
Area of Business/Research Focus
Upcoming SlideShare
Loading in...5
×

Dr. Jeffrey Scott

809

Published on

Published in: Health & Medicine, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
809
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Dr. Jeffrey Scott

  1. 1. A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology<br />How to maximize medical technology adoption by involving the right people at the right time throughout the product development process<br />Jeffrey R. Scott, Ph.D.<br />Principal Scientist<br />Preclinical Affairs<br />C.R. Bard, Inc. (Davol)<br />jeffrey.scott@crbard.com<br />
  2. 2. Background<br /><ul><li>B.Sc. Honors Life Science</li></ul> McMaster University, Canada<br /><ul><li>Ph.D. Medical Biophysics (Vascular Biology)</li></ul> University of Western Ontario, Canada<br /><ul><li>Post-Doc Surgery / Immunology</li></ul> Harvard Medical School, Boston, MA<br /><ul><li>Industry Preclinical Affairs</li></ul> C.R. Bard, Inc. (Davol), Warwick, RI<br />
  3. 3. Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
  4. 4. Area of Business/Research Focus
  5. 5. Rapid Innovation / Adoption
  6. 6. Surgeon Involvement During Product Development
  7. 7. The Benefits of Early Involvement</li></li></ul><li>Who is C.R. Bard, Inc. ?<br /><ul><li>C.R. Bard, Inc. was founded in 1907 by Charles Russell Bard
  8. 8. A publicly traded company – BCR
  9. 9. Market Cap: $9.3B, Annual Revenue of $2.8B
  10. 10. 11,700 employees worldwide
  11. 11. Headquartered in Murray Hill, NJ
  12. 12. 5 divisions - RI, Massachusetts, Georgia, Utah, Arizona
  13. 13. Vascular, Urology, Oncology, Surgical Specialties
  14. 14. Global presence </li></ul> Europe, Japan, Canada, Australia, Latin America, Asia, China<br />
  15. 15. Davol, Inc. History<br />Joseph Davol<br />Charles Davol<br />
  16. 16. Davol, Inc. History<br />1874: Davol Rubber Company founded to produce rubber medical and surgical supplies such as hot water bottles and catheters.<br />1923: C. R. Bard, Inc. is exclusive Davol Foley catheter distributor<br />1968: Davol, Inc. acquired by International Paper, Inc.<br />1971: Davol, Inc. headquarters moved from Providence to Cranston, RI.<br />1980: Acquired by C. R. Bard, Inc. from International Paper, Inc. for $48MM. Single largest selling product was the Foley catheter manufactured by Davol, Inc.<br />2008: Company moved from Cranston, RI to new division headquarters in Warwick, RI.<br />
  17. 17. C.R. Bard, Inc. (Davol) Today<br />Worldwide Leader in a $600M Hernia Repair Market<br /><ul><li>Provide innovative solutions to surgeons
  18. 18. Broadest/deepest product line in the industry
  19. 19. Portfolio of patented, proprietary products
  20. 20. Highly trained, professional sales team - surgeon consultants
  21. 21. Innovative Marketing Programs
  22. 22. Surgeon training
  23. 23. Patient education and awareness</li></li></ul><li>Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
  24. 24. Area of Business/Research Focus
  25. 25. Rapid Innovation / Adoption
  26. 26. Surgeon InvolvementDuring Product Development
  27. 27. The Benefits of Early Involvement</li></li></ul><li>Soft Tissue Reconstruction – Hernia Repair<br />
  28. 28. Soft Tissue Reconstruction – Hernia Repair<br />
  29. 29. Soft Tissue Reconstruction – Breast Reconstruction<br />
  30. 30. Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
  31. 31. Area of Business/Research Focus
  32. 32. Rapid Innovation / Adoption
  33. 33. Surgeon InvolvementDuring Product Development
  34. 34. The Benefits of Early Involvement</li></li></ul><li>Evolution of Ventral Hernia Mesh Repair <br />Tissue to Tissue Repair<br />LeBlanc – First Lap ePTFE Implant 5<br />Usher – First Marlex MeshRepair 1<br />Bauer – First ePTFE Implant 4<br />Bard Composix™ Kugel™ (CK)<br />ePTFE Invented – W. L. Gore<br />Rives-Stoppa Techniques 2, 3<br />Bard Composix™ E/X<br />Bard Composix™ L/P<br />Bard Composix™<br />Bard Ventralex™<br />Bard Ventrio™<br />Bard Dulex ™<br />1993<br />1997<br />1987<br />2001<br />1969<br />1976<br />1958<br />2003<br />2006<br />2008<br />50%<br />Emergence of Laparoscopy<br />Rate of Hernia Recurrence<br />< 10% <br />
  35. 35. Synthetic Inguinal Products<br />3DMax™ Mesh<br />PerFix™Plug<br />Bard® Soft Mesh<br />MK™Patch<br />Kugel™Patch<br />
  36. 36. Synthetic Ventral & Specialty Products<br />Composix™ EX Mesh<br />Ventralex™ Patch<br />Ventrio™ Patch<br />CruraSoft™ Hiatal Patch<br />Composix™ L/P Mesh<br />Sepramesh™ IP<br />CK™ Parastomal Patch<br />
  37. 37. Mesh Fixation<br />SorbaFix™ Absorbable Fixation Device<br />PermaSorb™ Absorbable Fixation Device<br />
  38. 38. Biologically-derived Implants<br />CollaMend™ FM Implant<br />AlloMax™ Surgical Graft<br />XenMatrix™ Surgical Graft<br />
  39. 39. Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
  40. 40. Area of Business/Research Focus
  41. 41. Rapid Innovation / Adoption
  42. 42. Surgeon InvolvementDuring Product Development
  43. 43. The Benefits of Early Involvement</li></li></ul><li>Product Development Process:<br />The Value of Surgeon Involvement<br />Product<br />Launch<br />Tech Dev<br />Concept<br />Feasibility<br />Development<br />New Ideas – Technique/Use<br />Clinically Relevant Problems<br />O.R. Interaction<br />User Needs<br />Focus Groups<br />Marketing Research<br />Concept Selection<br />Pilot Study Interaction<br />Design Validation<br />Product Interactions<br />Pivotal Study Interaction<br />Message Refinement<br />Design Validation<br />Scientific Communication<br />Podium Presence<br />Surgeon Education<br />
  44. 44. Where does innovation happen?<br />Office<br />
  45. 45. Where does innovation happen?<br />Lab<br />
  46. 46. Where does innovation happen?<br />O.R.<br />
  47. 47. Where does innovation happen?<br />What is the impact on adoption?<br />Office<br />O.R.<br />Lab<br />Better Products & Rapid Adoption<br />
  48. 48. Animal Models Developed<br />in vivo: Open / Laparoscopic Ventral Hernia Repair<br />Rat:Long-term Material Characterization / Adhesion Assessment / Infection<br />Rabbit: Mid-term Material Characterization / Adhesion Assessment / Infection<br />Pig: Short-term (Clinically-Relevant) Material / Adhesion Assessment<br />Mini-Pig: Long-term (Clinically-Relevant) Material / Adhesion Assessment<br />ex vivo: Hernia Repair Assessment<br />PAW: Mechanical Assessment: Fixation, Burst; Laparoscopic Insertion<br />
  49. 49. Animal Models Developed - Laparoscopic<br />
  50. 50. Animal Models Developed - Open<br />
  51. 51. Animal Models Developed – Breast Reconstruction<br />
  52. 52.
  53. 53. Agenda<br /><ul><li>Brief History of C.R. Bard, Inc. (Davol)
  54. 54. Area of Business/Research Focus
  55. 55. Rapid Innovation
  56. 56. Surgeon InvolvementDuring Product Development
  57. 57. The Benefits of Early Involvement</li></li></ul><li>Surgeon Involvement - Primary Benefits<br /><ul><li> User Needs are Addressed in Your Products
  58. 58. Products are Safer and More Effective
  59. 59. Maximize Return on Research Investment
  60. 60. Strong Podium Presence at Launch
  61. 61. Surgeon Education</li></ul>Rapid Product Adoption<br />
  62. 62. A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology<br />How to maximize medical technology adoption by involving the right people throughout the product development process<br />Jeffrey R. Scott, Ph.D.<br />Principal Scientist<br />Preclinical Affairs<br />C.R. Bard, Inc. (Davol)<br />jeffrey.scott@crbard.com<br />

×